最新ニュース Pfizer (NYSE:PFE) 株価情報

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Options

Markets

資金力を持つ投資家たちは、ファイザー（NYSE:PFE）に対して積極的なアプローチをとっており、市場プレイヤーが無視すべきではないと言えるでしょう。 Benzingaが公開したオプションの記録を追跡したところ、今日この重要な動きが明らかになりました。

ファイザーのオプション取引｜慎重な取引を

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug costs</a>.
These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.
The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.
Under the finalized <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower" rel="noreferrer noopener">guidance</a> for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.
The selected drug list for the second cycle of negotiations is:&nbsp;
<ul>
<li>Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.</li>
<li>Pfizer Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Ibrance for breast cancer and Xtandi for prostate cancer.</li>
<li>GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.</li>
<li>Teva Pharmaceutical Industries Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.</li>
<li>Abbvie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess and depression drug Vraylar.</li>
<li>Bristol-Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Pomalyst for a type of blood cancer.</li>
<li>Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.</li>
<li>AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug Calquence</li>
<li>Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan</li>
<li>Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) diabetes drug Janumet; Janumet XR.</li>
<li>Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) psoriasis drug Otezla</li>
</ul>
CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.
The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.
The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">estimated $1.5 billion</a>.
Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles. The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43055401/schlumberger-posts-strong-q4-results-raises-dividend-and-buybacks-championx-deal-to-strengthen-future-growth" target="_blank" rel="noreferrer noopener">Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More</a></li>
</ul>
Image via Shutterstock

Biotech

Government

Large Cap

News

Regulations

Health Care

General

ABBV

AMGN

TEVA

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

Activist investor Starboard Value LP has reportedly acquired a 7.7% stake worth approximately $500 million in Qorvo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) on Thursday, targeting the struggling semiconductor manufacturer for potential operational changes.
What Happened: The stake, led by Starboard CEO Jeff Smith, comes as Qorvo faces mounting challenges in the radio frequency chip market, reported the Wall Street Journal, <a href="https://www.wsj.com/finance/starboard-builds-big-stake-in-chip-maker-qorvo-7a18a71f">citing</a> sources. 
The Greensboro, N.C.-based company&#8217;s shares have declined nearly 28% over the past year amid intensifying competition from rivals like Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Skyworks Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>).
The investment represents a return to familiar territory for Starboard, which previously held a position in TriQuint Semiconductor before its 2014 merger with RF Micro Devices to form Qorvo. The activist firm has maintained a strong presence in the semiconductor sector, with past investments in NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>).
Qorvo&#8217;s recent performance has worried investors, with the company&#8217;s shares tumbling after missing Wall Street&#8217;s quarterly projections. CFO Grant Brown acknowledged these challenges in October, citing weaker demand for premium smartphones and announcing factory consolidation efforts to improve profitability.
Qorvo did not immediately respond to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43047812/bill-ackman-calls-hindenburg-researchs-closure-a-big-loss-praises-short-sellers-contribution-to-capital-markets">Bill Ackman Says Hindenburg Research Closing &#8216;A Big Loss,&#8217; Praises Short Seller&#8217;s Contribution To Markets: &#8216;Short Selling Is Really Hard&#8217;</a>
Why It Matters: The chip maker, currently valued at approximately $7 billion, has struggled to maintain its market position as consumers shift toward entry-level Android devices. Wall Street analysts maintain a <a href="https://www.benzinga.com/quote/QRVO/analyst-ratings">consensus price target</a> of $97.65, though recent assessments from Goldman Sachs, Mizuho, and Loop Capital suggest more modest expectations with an average target of $77.
<figure class="wp-block-image aligncenter size-large is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/17000713/Screenshot-2025-01-17-at-10.36.23%E2%80%AFAM-1024x376.png" alt="" class="wp-image-738146" style="width:540px;height:auto" /></figure>
Starboard&#8217;s investment in Qorvo adds to its <a href="https://www.benzinga.com/markets/equities/24/10/41419988/tylenol-listerine-maker-kenvue-under-activist-spotlight-with-starboard-value-stake-overhaul-ahea">recent string of activist positions</a>, including stakes in Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), and Riot Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>).
Price Action: Qorvo surged 7.08% in after-hours trading to $78.80 on Thursday. The stock closed at $73.59, down 0.77% on the regular trading session, and has fallen 27.43% over the past year, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43047766/jim-cramer-questions-nvidias-trading-pattern-amid-positive-tsmc-earnings-and-bidens-china-export-regulations">Jim Cramer Questions Nvidia&#8217;s Trading Pattern Amid Positive TSMC Earnings And Biden&#8217;s China Export Regulations</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

AVGO

KVUE

MRVL

NVDA

QRVO

RIOT

SWKS

Qorvo Soars 7% After Hours As Activist Investor Starboard Reportedly Takes Stake In Semiconductor Company

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Albert Bourla, Chairman and CEO, said, &#8220;I think we did significant transformative changes in Pfizer.&#8221;
Pfizer&#8217;s CEO stated that the company revamped its commercial strategy, brought in new leadership, and exceeded market share expectations. On the cost side, Pfizer achieved $4 billion in savings and announced an additional $1.5 billion in margin improvements.
In R&amp;D, leadership <a target="_blank" href="https://investors.pfizer.com/files/doc_events/2025/Jan/13/PFE-USQ_Transcript_2025-01-13.pdf" rel="noreferrer noopener">changed</a> for the first time in 15 years, with Mikael Dolsten stepping down, and the team underwent a restructuring. Bourla also highlighted returns to shareholders, including over $7 billion in dividends and $4.5 billion toward debt repayment in the first nine months.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42873977/safety-labels-updated-for-pfizer-and-gsks-rsv-vaccines-fda-adds-warning-for-rare-neurological-disorder" rel="noreferrer noopener">Pfizer And GSK&#8217;s RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder</a>
Looking at the period from 2025 to 2030, Pfizer is facing a significant loss of exclusivity (LOE) wave that will reduce revenues by about $17-18 billion between 2026 and 2028.
Bourla said the products acquired are projected to bring in $20 billion in revenue by 2030, which should offset those losses and provide some growth.
Additionally, the company is counting on revenues from products already launched and others in the pipeline. This is where the gap lies between Pfizer&#8217;s outlook and market expectations.
While new product launches in 2023 were underwhelming, Pfizer made significant progress in 2024, which makes the company optimistic about future performance.
When asked about the visibility into the business, Albert Bourla added that the main difference between 2024 and 2025 is the stabilization of the COVID business.
In 2024, guidance reflected significant uncertainty, partly due to miscalculations in COVID-19 revenue, the transition of Paxlovid to a commercial model, and contract renegotiations with Europe. As a result, Pfizer was cautious when setting expectations.
For 2024, the company reconfirmed guidance in December. For 2025, projections are similarly strong, with COVID revenues expected <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42530634/pfizer-does-not-anticipate-material-changes-to-us-vaccine-policy-from-the-incoming-administration-in-2025" rel="noreferrer noopener">to remain stable</a>.
Vaccination rates are low but consistent, and Pfizer anticipates achieving similar results in 2025 as in 2024.
For Paxlovid, demand closely tracks COVID waves, which have followed a predictable pattern over the last three years—two waves annually. Overall, the company foresees stability in our COVID business moving forward.
Price Action: PFE stock is down 1.49% at $26.40 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42978906/regeneron-pipeline-aims-to-address-220-billion-therapeutic-opportunities-by-2030" target="_blank" rel="noreferrer noopener">Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030</a></li>
</ul>
Photo via Shutterstock

Guidance

Trading Ideas

Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges

Clinical research organization ICON plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) announced its financial guidance for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42971328/icon-issues-financial-guidance-for-full-year-2025" rel="noreferrer noopener">fiscal year 2025 on Tuesday</a>.
What Happened: The Dublin-based company forecasts revenues of $8.05 billion — $8.65 billion. This represents growth of about 1% at the midpoint compared to the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $8.5 billion</a>.
The company expects adjusted earnings per share to be in the range of $13 to $15. That&#8217;s flat over the full-year 2024 adjusted earnings per share guidance midpoint compared to the consensus of $14.83.
See Also: <a href="https://www.benzinga.com/25/01/42980742/trump-off-hook-in-2020-election-case-special-counsel-smith-says-evidence-was-sufficient-to-obtain-and-sustain-a-conviction">Trump&#8217;s 2024 Election Win Spares Him From &#8216;Conviction&#8217; In Jan. 6 Case, Special Counsel Says</a>
ICON CEO Steve Cutler says trial activity has been &#8220;impacted by cautious spending from biopharma customers in both the biotech and large pharma businesses.&#8221; 
The company&#8217;s outlook for this year reflects an expected transition period, which includes a headwind from its top two customers on a combined basis, coupled with &#8220;an inconsistent recovery in biotech,&#8221; he added.
For fiscal year 2024, the company reaffirmed its current guidance of revenue of $8.26 billion — $8.3 billion and adjusted EPS of $13.90 &#8211; $14.10 versus consensus of $8.28 billion and $13.98, respectively.
Why It Matters: William Blair analysts are &#8220;surprised by the size of the topline cut relative to management&#8217;s initial thoughts last quarter (anticipated revenue growth in the low to mid-single digits for this year).&#8221;
Analyst Max Smock expects the company to face challenges in understanding &#8220;cautious spending patterns&#8221; from biopharma clients, including Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
There&#8217;s also uncertainty about when biotech demand will stabilize. Investors debate whether $14 or $15 per share was the right target for the quarter.
The initial guidance for next year will lean closer to $15, observers say. However, margins will face more pressure than expected.
Price Action: Icon stock is down 6.96% at $202.81 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" target="_blank" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a></li>
</ul>
Image: Shutterstock

Analyst Color

Analyst Ratings

Movers

ICLR

Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$25.00</td>
<td>$380.0K</td>
<td>2.3K</td>
<td>3.5K</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$115.00</td>
<td>$64.3K</td>
<td>26</td>
<td>3.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$26.00</td>
<td>$48.1K</td>
<td>12.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ONC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$40.5K</td>
<td>0</td>
<td>406</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$75.0K</td>
<td>39</td>
<td>302</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$175.00</td>
<td>$90.1K</td>
<td>7.2K</td>
<td>170</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$40.7K</td>
<td>203</td>
<td>167</td>
</tr>
<tr>
<td>OPCH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$37.6K</td>
<td>208</td>
<td>157</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$55.00</td>
<td>$55.3K</td>
<td>421</td>
<td>154</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$30.6K</td>
<td>556</td>
<td>139</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option trade with neutral sentiment. It expires in 66 day(s) on March 21, 2025. Parties traded 1000 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $380.0K, with a price of $380.0 per contract. There were 2393 open contracts at this strike prior to today, and today 3522 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bullish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 99 contract(s) at a $115.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $64.3K, with a price of $645.0 per contract. There were 26 open contracts at this strike prior to today, and today 3057 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 501 contract(s) at a $26.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $48.1K, with a price of $96.0 per contract. There were 12780 open contracts at this strike prior to today, and today 1248 contract(s) were bought and sold. 
• Regarding ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 33 contract(s) at a $180.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $40.5K, with a price of $1230.0 per contract. There were 0 open contracts at this strike prior to today, and today 406 contract(s) were bought and sold. 
• For BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $145.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $75.0K, with a price of $750.0 per contract. There were 39 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 142 contract(s) at a $175.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $90.1K, with a price of $635.0 per contract. There were 7210 open contracts at this strike prior to today, and today 170 contract(s) were bought and sold. 
• Regarding HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 167 contract(s) at a $35.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $40.7K, with a price of $245.0 per contract. There were 203 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
• Regarding OPCH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on January 17, 2025. Parties traded 47 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $801.0 per contract. There were 208 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a put option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 82 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $55.3K, with a price of $679.0 per contract. There were 421 open contracts at this strike prior to today, and today 154 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bearish, expiring in 3 day(s) on January 17, 2025. This event was a transfer of 42 contract(s) at a $580.00 strike. The total cost received by the writing party (or parties) was $30.6K, with a price of $730.0 per contract. There were 556 open contracts at this strike prior to today, and today 139 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIIB

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HROW

OPCH

PRAX

10 Health Care Stocks With Whale Alerts In Today's Session

Offerings

Asset Sales

Pfizer To Sell 700M Ordinary Shares In Haleon; Pfizer's Stake In Haleon To Reduce From 15.0% To 7.3%

Pfizer CEO Albert Bourla Says "Looking At Everything" In The Obesity Market Beyond Injectable GLP-1 Drugs; Says "All In" On Obesity Drug Development

Whales with a lot of money to spend have taken a noticeably bullish stance on Pfizer.
Looking at options history for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 41% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $259,111 and 7, calls, for a total amount of $504,338.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $18.0 to $42.0 for Pfizer over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Pfizer stands at 4862.2, with a total volume reaching 36,883.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Pfizer, situated within the strike price corridor from $18.0 to $42.0, throughout the last 30 days.
<h3>Pfizer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736784930_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$0.19</td>
<td>$0.17</td>
<td>$0.17</td>
<td>$24.00</td>
<td>$124.0K</td>
<td>22.0K</td>
<td>7.3K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$1.49</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$25.00</td>
<td>$121.1K</td>
<td>331</td>
<td>3.5K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.9</td>
<td>$8.5</td>
<td>$8.65</td>
<td>$18.00</td>
<td>$108.1K</td>
<td>465</td>
<td>0</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.55</td>
<td>$6.45</td>
<td>$6.45</td>
<td>$20.00</td>
<td>$87.7K</td>
<td>3.1K</td>
<td>136</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.55</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$20.00</td>
<td>$65.0K</td>
<td>1.7K</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
<h3>Pfizer's Current Market Status</h3>
<ul>
<li>With a volume of 7,971,307, the price of PFE is down -0.67% at $26.54. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 22 days.</li>
</ul>
<h3>What The Experts Say On Pfizer</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $30.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on Pfizer, which currently sits at a price target of $32. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Pfizer, targeting a price of $29. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Pfizer's Options Market Dynamics

On Thursday, Truist initiated coverage on BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development <a target="_blank" href="https://www.benzinga.com/24/12/42370209/why-is-biontech-stock-trading-higher-on-friday" rel="noreferrer noopener">and upcoming catalysts.</a>
The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41866389/biontech-earns-upgrade-from-goldman-sachs-as-investment-thesis-shifts-toward-cancer-potential" rel="noreferrer noopener">BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential</a>
While Summit Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) ivonescimab may have a head start in certain areas, BioNTech&#8217;s stronger financial position and pipeline of complementary products give it a strategic edge. With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds.
In November, BioNTech agreed to acquire&nbsp;Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41949384/biontech-boosts-oncology-strategy-with-800-million-china-based-biotheus-acquisition" rel="noreferrer noopener">oncological or inflammatory diseases</a>.
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
Truist initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/BNTX/analyst-ratings" rel="noreferrer noopener">price target of $172</a>.
BioNTech&#8217;s oncology pipeline was previously seen as limited in value outside BNT316. However, with BNT327 gaining traction and new data expected in 2025 to clarify the potential of other pipeline assets, there is room for greater investor appreciation of the company&#8217;s oncology portfolio, Truist analyst adds.
Goonewardene also writes that <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">COVID-19 remains a significant factor</a> in BioNTech&#8217;s stock performance and that COVID-related developments will continue to influence BioNTech&#8217;s stock.
The analyst highlights that BNT327 could be the first drug approved in the U.S. and Europe for key conditions like triple-negative breast cancer and small cell lung cancer, potentially generating around $2 billion at peak sales.
For non-small cell lung cancer, Truist expects BNT327 to follow shortly, contributing over $4 billion in revenue.
Price Action: BNTX stock is up 0.55% at $122.82 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42918973/wayfair-waves-goodbye-to-germany-heres-why" target="_blank" rel="noreferrer noopener">Wayfair Waves Goodbye To Germany &#8211; Here&#8217;s Why</a></li>
</ul>
Image via Shutterstock.

Price Target

Initiation

BNTX

SMMT

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

On Friday, Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance for BCG-naïve, high-risk non-muscle <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42908491/pfizers-sasanlimab-in-combination-with-bcg-improves-event-free-survival-in-patients-with-bcg-na-ve" rel="noreferrer noopener">invasive bladder cancer (NMIBC)</a>.
The study met its primary endpoint of event-free survival by investigator assessment, showing a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG as compared to BCG alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42873977/safety-labels-updated-for-pfizer-and-gsks-rsv-vaccines-fda-adds-warning-for-rare-neurological-disorder" rel="noreferrer noopener">Pfizer And GSK&#8217;s RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder</a>
Each year, around 100,000 individuals worldwide receive a diagnosis of high-risk NMIBC.
The overall safety profile of sasanlimab in combination with BCG was generally consistent with the known profile of BCG and data reported from clinical trials with sasanlimab.
The profile of sasanlimab was also generally consistent with the reported safety profile of PD-1 inhibitors.
The company plans to submit results for presentation at an upcoming medical congress.
Pfizer intends to discuss these data with global health authorities to support potential regulatory filings. Sasanlimab also continues to be investigated in combination with Pfizer&#8217;s antibody-drug conjugate portfolio in advanced solid tumors.
Price Action: PFE stock is up 0.28% to $26.94 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/42913319/beer-maker-constellation-brands-q3-sales-hit-by-subdued-spending-stock-slides" target="_blank" rel="noreferrer noopener">Beer Maker Constellation Brands&#8217; Q3 Sales Hit By Subdued Spending; Stock Slides</a></li>
</ul>
Image via Shutterstock.

Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are just "too low to sell," according to Jim Cramer, host of CNBC&#8217;s "<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>." 
Hold the stock and let "the dividend do the job," Cramer advises, preferring to wait for "some good news" <a href="https://www.benzinga.com/general/biotech/23/03/31319372/seagens-43b-deal-to-double-pfizers-early-stage-oncology-pipeline-seagen-says-is-right-step">on the Seagen acquisition</a>.
Pfizer stock is down more than 7% over the past year. With the Covid wave having past, the pharma giant is in talks to extend its collaboration with medical AI start-up firm PostEra to design antibody-drug conjugates.
Turning to Vertex Pharmaceuticals Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) new wonder drug suzetrigine, which received FDA approval last year, Cramer said it was disappointing that the drug does not seem to be working. "I was praying they would have something that wouldn&#8217;t be addictive," he added.
Although the pharma company has several "great drugs," there seems to be a limited upside to the stock because suzetrigine was supposed to be the "drug of the future for Vertex," Cramer added.
When asked about Serve Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>), Cramer suggested Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) for exposure to the sector. Calling Nvidia the "king of robots," he further said, "There's nobody else."
Cramer said he would be a seller of QuantumScape Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>). Referring to the steep decline in Powell Industries Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) shares, Cramer said, "I did not see that coming." The decline has been a "big, big disappointment," he added.
Price Action
<ul>
<li>Pfizer's stock declined by 1% to close at $26.86 on Wednesday.</li>
<li>Shares of Vertex Pharmaceuticals Inc settled higher by 0.93% at $412.11.</li>
<li>Serve Robotics tanked almost 10% on Wednesday.</li>
<li>Nvidia's share price ended the trading session almost flat.</li>
<li>QuantumScape's stock plunged 9% to close at $5.72.</li>
<li>Shares of Powell Industries fell 3.26% to $229.38.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42900074/how-to-earn-500-a-month-from-synovus-financial-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Synovus Financial Stock Ahead Of Q4 Earnin</a>gs</li>
</ul>
Image: Shutterstock

Media

POWL

SERV

VRTX

Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure

The company announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG (induction and maintenance) as compared to BCG alone (induction and maintenance).

Pfizer Says Its Sasanlimab In Combination With Bacillus Calmette-Guérin (BCG) Improves Event-Free Survival In Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

GILD

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

The U.S. reported its <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">first human death</a> from the H5 bird flu strain this week, causing a spike in vaccine developer stocks Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), CureVac (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
Vaccine production efforts are ramping up as health officials monitor the outbreak closely. In<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html" target="_blank" rel="noreferrer noopener"> an update </a>on Monday, CDC said there have been 66 confirmed cases in the U.S. in the 2024 outbreak. 
CDC said the public risk remains low. Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
See Also: <a href="https://www.benzinga.com/news/25/01/42851023/why-novavax-nvax-stock-is-rising">Why Novavax (NVAX) Stock Is Rising</a>
<h3 class="wp-block-heading">Vaccine Providers in the Limelight</h3>
In the U.S., vaccines against H5N1 are already stockpiled. Approved shots include those from Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), CSL Seqirus, and ID Biomedical Corporation of Quebec, a subsidiary of GlaxoSmithKline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), which collectively secured $72 million in funding from the U.S. health department in October to boost the production of bird flu vaccines. These traditional vaccines, developed years ago, target older H5N1 strains but are expected to offer some protection.
Moderna, backed by $176 million from the U.S. government's BARDA, is working on an updated mRNA H5N1 vaccine. Other players, including Pfizer and GSK (in collaboration with CureVac), are testing similar candidates.
<h3 class="wp-block-heading">ETFs in Focus</h3>
For investors who want to play the trend but are wary of choosing individual biotech stocks, here are three ETFs that offer diversified exposure to the biotech companies leading the vaccine efforts. With a mix of traditional and mRNA vaccine developers in focus, these funds could benefit as the world prepares for a potential bird flu pandemic.
iShares Genomics Immunology and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NYSE">IDNA</a>) tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index, and has already gained 2.5% so far this year. The fund has an expense ratio of 0.47%, and $129.97 million in assets under management (AUM). The fund has currently invested 4.48% of its assets in Moderna. Sanofi, GSK and Novavax are also part of its portfolio of 51 equity holdings.
First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>) derives its investment strategy from the Nasdaq US Benchmark Index, and has an expense ratio of 0.60%. Pfizer is one of its top holdings, with 7.28% of assets allocated to it.
SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) mirrors the S&amp;P&nbsp;Biotechnology Select Industry&nbsp;Index, and charges a 0.35% expense ratio. Out of its present AUM of $6.37 billion, Moderna holds 2.58%. Almost 100% of its holdings are exposed to the biotechnology sector, with only about 0.04% invested in the pharmaceutical sector.
<h3 class="wp-block-heading">The Bird Flu Menace </h3>
The bird flu scare in humans ratcheted higher in late 2024 when a 13-year-old girl in Canada fell critically ill with H5N1 and required a ventilator. Around the same time, the U.S. reported its first severe case in an elderly patient in Louisiana.
Health experts warn that vigilance is key to preventing mutations that could trigger a pandemic. While the technology to develop vaccines quickly is available, governments may need to fund large-scale clinical trials in advance to ensure rapid distribution in case of a health emergency.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42878295/quantum-stocks-tumble-why-rigetti-ionq-and-d-wave-are-falling">Quantum Stocks Tumble: Why Rigetti, IonQ and D-Wave Are Falling</a></li>
</ul>
Photo: Shutterstock.

Sector ETFs

ETFs

CVAC

FTXH

IDNA

MRNA

NVAX

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

High-rolling investors have positioned themselves bearish on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in PFE often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for Pfizer. This is not a typical pattern.
The sentiment among these major traders is split, with 30% bullish and 70% bearish. Among all the options we identified, there was one put, amounting to $64,200, and 9 calls, totaling $566,920.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $28.0 for Pfizer over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Pfizer's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale trades within a strike price range from $20.0 to $28.0 in the last 30 days. 
<h3>Pfizer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736358367_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.18</td>
<td>$1.17</td>
<td>$1.17</td>
<td>$28.00</td>
<td>$171.7K</td>
<td>36.1K</td>
<td>1.6K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.35</td>
<td>$0.31</td>
<td>$0.33</td>
<td>$27.00</td>
<td>$78.2K</td>
<td>10.4K</td>
<td>3.2K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.6</td>
<td>$6.95</td>
<td>$7.0</td>
<td>$20.00</td>
<td>$70.0K</td>
<td>5.9K</td>
<td>1</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.2</td>
<td>$7.15</td>
<td>$7.2</td>
<td>$20.00</td>
<td>$68.2K</td>
<td>5.9K</td>
<td>107</td>
</tr>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.07</td>
<td>$0.87</td>
<td>$1.07</td>
<td>$28.00</td>
<td>$64.2K</td>
<td>190</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Pfizer</h3>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
<h3>Current Position of Pfizer</h3>
<ul>
<li>Currently trading with a volume of 13,755,318, the PFE's price is down by -1.46%, now at $26.73. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>Professional Analyst Ratings for Pfizer</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $30.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Pfizer with a target price of $29. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Pfizer, maintaining a target price of $32. 
&#x2A; Maintaining their stance, an analyst from Guggenheim continues to hold a Buy rating for Pfizer, targeting a price of $33. 
&#x2A; An analyst from B of A Securities downgraded its action to Neutral with a price target of $29. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Pfizer, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Pfizer: Analyzing the Surge in Options Activity

UBS analyst Colin Bristow maintains Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral and lowers the price target from $31 to $29.

UBS Maintains Neutral on Pfizer, Lowers Price Target to $29

The U.S. Food and Drug Administration (FDA) has mandated updates to the safety labeling for Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo and GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Arexvy respiratory syncytial virus (RSV) vaccines.
New warnings in the prescribing information highlight a potential increased risk of Guillain-Barré syndrome (GBS), a rare neurological disorder, within 42 days of vaccination based on findings from a postmarketing observational study.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
GBS, a condition in which the immune system attacks nerve cells, can lead to muscle weakness and, in severe cases, paralysis.
According to the FDA, while the evidence suggests an elevated risk, it is insufficient to confirm a definitive causal link between the vaccines and the disorder.
This determination is <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and" rel="noreferrer noopener">based</a> on data from clinical trials, adverse event reports, and an observational study conducted among Medicare beneficiaries aged 65 and older.
The study, conducted between May 2023 and July 2024, utilized Medicare claims to identify cases of hospitalized GBS in individuals vaccinated with Abrysvo or Arexvy.
Using a self-controlled case series analysis, researchers compared risk windows of 1-42 days post-vaccination with control windows of 43-90 days. The findings estimate nine excess GBS cases per million doses of Abrysvo and seven per million doses of Arexvy administered to individuals aged 65 and older.
These risks reflect excess cases compared to background rates of GBS in the studied population. However, variations in background risks and analytical methods make direct comparisons to other studies challenging. The FDA emphasized that while increased risks were observed, further investigation is needed to fully understand the connection between the vaccines and GBS.
U.S. sales of RSV vaccines&nbsp;have declined after regulators narrowed the age group eligible for the shots and determined they would be a one-time vaccination for now.
For Pfizer and GSK, RSV vaccines are critical as they seek to build new revenue streams before facing generic competition for their <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41278571/gsk-pfizer-face-declining-respiratory-syncytial-virus-vaccine-sales-due-to-narrow-age-recommendat" rel="noreferrer noopener">top-selling drugs</a>.
Price Action: GSK stock is down 1.55% at $33.56, and PFE stock is down 0.18% at $27.08 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/42868870/amazon-web-services-expands-in-asia-pacific-with-5-billion-investment-in-thailand-region" target="_blank" rel="noreferrer noopener">Amazon Web Services Expands In Asia Pacific With $5 Billion Investment In Thailand Region</a></li>
</ul>
Photo via Shutterstock

Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder

<a href="https://www.ft.com/content/ad6a2867-80e0-4f9b-b59e-8d88c17ffbaa" title="https://www.ft.com/content/ad6a2867-80e0-4f9b-b59e-8d88c17ffbaa">https://www.ft.com/content/ad6a2867-80e0-4f9b-b59e-8d88c17ffbaa</a>

Politics

'Pfizer executives descend on Donald Trump's Mar-a-Lago for planning meeting' - Financial Times

PostEra Expands AI Drug Discovery Collaboration With Pfizer To $610M, Launches New Antibody-Drug-Conjugate Partnership And Extends Existing $260M AI Lab Initiative

AbbVie retains Humira market share above 70%: report

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more... The pharmaceutical sector plays a crucial role in tackling global health issues, from combating infectious diseases to addressing chronic illnesses. The companies in this sector are not only developing groundbreaking treatments but also improving access to life-saving drugs.
Amid this backdrop, investors looking to tap into the pharmaceutical sector might consider buying these three fundamentally strong pharma stocks Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), and Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>) for potential gain.
As the world faces rising healthcare demands, innovative pharmaceutical firms are stepping up to meet these challenges. Technological advancements such as AI-driven drug discovery and precision medicine enable faster development of treatments and personalized care, <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality">addressing the unique needs of individual patients</a>. Pharmaceutical manufacturers are already using Gen AI foundational models to identify targets, develop validation assays, and assist in preclinical testing to determine their effectiveness.
One of the key drivers of growth in the pharmaceutical sector is the rising prevalence of non-communicable diseases such as diabetes, cardiovascular conditions, and cancer. Companies investing in advanced therapies, including biologics and gene editing, are positioned to benefit from this trend. With <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">50 novel drugs approved by the U.S. Food and Drug Administration (FDA)</a> in 2024, the pharmaceutical sector is likely to see sustained growth and long-term relevance.
Furthermore, the U.S. pharmaceutical market is anticipated to reach $764.06 billion by 2033, <a href="https://www.grandviewresearch.com/industry-analysis/us-pharmaceuticals-market-report#:~:text=The%20U.S.pharmaceutical%20market%20is%20expected%20to%20grow%20at%20a,USD%200.76%20billion%20by%202030.">exhibiting a CAGR of 5.5%</a>.
Now, let us dive deep into the fundamentals of three <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> stocks, starting with third.
Stock #3: Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE is a global leader in biopharmaceuticals, offering a wide range of medicines and vaccines across several therapeutic areas. Its diverse portfolio spans treatments for cardiovascular conditions, metabolic issues, migraines, women's health, and infectious diseases, including COVID-19 prevention and treatment. It also explores future mRNA and antiviral therapies and provides biosimilars for chronic immune and inflammatory conditions.
On December 20, PFE received approval from the U.S. Food and Drug Administration (FDA) for BRAFTOVI&#xAE; (encorafenib) in combination with cetuximab and mFOLFOX6 for the treatment of patients with BRAF V600E-Mutant metastatic colorectal cancer. This approval is first-in-line in the development of innovative medicines for the hardest-to-treat cancers, also expanding PFE's portfolio.
Moreover, on November 20, PFE announced that it received approval from the European Commission (EC) for HYMPAVZI for the routine prevention of bleeding episodes in patients 12 years of age and older weighing at least 35 kg with severe hemophilia A without FVIII inhibitors or severe hemophilia B without FIX inhibitors. this approval will strengthen PFE's position in the genetic disease treatment market as HYMPAVZI is the first and only anti-tissue factor pathway inhibitor approved by EC.
PFE pays a $1.72 per share dividend annually, translating to a 6.72% yield on the current share price. Its four-year dividend yield is 4.32%.
PFE's total revenues for the third quarter (ended September 30, 2024) increased 31.2% year-over-year to $17.70 billion. The company's non-GAAP net income stood at $6.05 billion compared to the prior-year quarter's loss of $968 million, while its <a href="https://www.investopedia.com/terms/e/eps.asp">earnings per share</a> came in at $1.06 versus a loss of $0.17 per share last year.
As a result of its impressive performance, the company updated its fiscal year 2024 financial guidance, increasing its revenue projection to a range of $61 billion to $64 billion, up from the previous estimate of $59.50 billion to $62.50 billion. Additionally, it has raised its adjusted EPS guidance to a new range of $2.75 to $2.95, higher than the prior forecast of $2.45 to $2.65.
Analysts expect PFE's revenue for the fourth quarter (ended December 2024) to grow 20.3% year-over-year to $17.14 billion, while its EPS for the same period is expected to increase 360.4% from the prior year-quarter to $0.46. Moreover, the company has surpassed Street revenue and EPS estimates in three of the trailing four quarters.
Shares of PFE have surged 4.5% over the past month to close the last trading session at $26.72.
PFE's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect this robust outlook. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
PFE has an A grade for Growth and a B for Value. It is ranked #34 out of 151 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to see the additional ratings for PFE (Momentum, Stability, Sentiment, and Quality).
Stock #2: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ is engaged in the research and development, manufacture, and sale of healthcare products primarily focused on human health and well-being. The company offers a diversified range of products through the Innovative Medicine segment and MedTech segment.
On January 10, JNJ announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH&#x2122; SF Catheter for the treatment of cardiac arrhythmias. This offers electrophysiologists the ability to switch between radiofrequency and pulsed field energy in a single, fully integrated catheter, delivering safe and effective procedures for patients.
On December 30, JNJ announced that it had received the European Commission approval for RYBREVANT&#xAE; (amivantamab) in combination with LAZCLUZE&#x2122; (lazertinib) for the first-line treatment of advanced non-small cell lung cancer (NSCLC) in adults with EGFR mutations. This multitargeted, chemotherapy-free combination as shown superior efficacy compared to Osimertinib monotherapy for treating EGFR-mutated NSCLC.
For the nine-month period that ended September 30, 2024, JNJ's sales to customers increased 4% year-over-year to $66.30 billion. Its gross profit rose 4.5% from the year-ago value to $45.96 billion. The company's net earnings from continuing operations amounted to $6.84 billion, representing a 15.7% increase from the same period last year. Also, its net earnings per share from continuing operations for the period increased 24.1% year-over-year to $4.38.
JNJ's revised outlook for the fiscal year 2024 anticipates operational sales in the range of $89.40 billion to $89.80 billion, marking a 6.6% growth compared to 2023, largely fueled by recent acquisitions. The company also projects adjusted EPS between $9.88 and $9.98.
Street expects JNJ's revenue for the fiscal year (ended December 2024) to increase 4.3% year-over-year to $88.78 billion. Its EPS for the same year is expected to register a marginal growth from the prior year, settling at $9.96.
JNJ shares have declined marginally intraday, closing the last trading session at $142.06.
JNJ's strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
JNJ has a B grade for Value, Stability, Sentiment, and Quality. It is ranked #14 in the same industry.
<a href="https://stocknews.com/stock/JNJ/">Click here</a> to see the additional ratings for JNJ (Growth and Momentum).
Stock #1: Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>)
MRK is a global healthcare company offering health solutions through its prescription medicines, including biological therapies, vaccines, and animal health products. It operates through two segments: Pharmaceutical and Animal Health.
On January 8, MRK announced the National Medical Products Administration (NMPA) of China approved GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine] for use in males aged 9 to 26. This approval makes GARDASIL the first HPV vaccine in China, helping MRK strengthen its position.
On December 20, MRK announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, from LaNova Medicines Ltd. This agreement will allow MRK to develop, manufacture, and commercialize LM-299.
During the nine-month period ended September 30, 2024, MRK's sales increased 6.7% year-over-year to $48.54 billion, while its pharmaceutical segment's sales improved by 7.2% from the prior year's value to $43.36 billion. The company's net income attributable rose significantly from the year-ago value to $13.37 billion, while its EPS stood at $5.26, up considerably year-over-year.
According to the full-year 2024 guidance, MRK forecasts worldwide sales to range from $63.60 billion to $64.10 billion, an increase from the previous guidance of $63.40 billion to $64.40 billion. The company also expects non-GAAP EPS to be between $7.72 and $7.77.
The consensus revenue estimate of $15.52 billion for the fiscal fourth quarter (ending December 2024) represents a 6.1% increase year-over-year. The consensus EPS estimate of $1.79 for the current quarter indicates a considerable improvement year-over-year.
The company has an impressive surprise history; it surpassed the consensus revenue and EPS estimates in each of the trailing four quarters.
The stock declined marginally intraday, closing the last trading session at $99.25.
MRK's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It also has an A grade for Quality and a B for Value and Stability. Within the same industry, it is ranked #10.
<a href="https://stocknews.com/stock/MRK/">Click here</a> to see MRK's ratings for Growth, Momentum, and Sentiment.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
&nbsp;

<hr />
JNJ shares were trading at $143.12 per share on Monday morning, up $1.06 (+0.75%). Year-to-date, JNJ has declined -1.04%, versus a -1.64% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: ShreyaRathi</h2> <img src='https:/wp-content/uploads/2024/10/0.jpeg' style="float:left; padding:5px;width:125px;"><a href="https://stocknews.com/authors/?author=shreya-rathi">More...</a>The post <a href=https://stocknews.com/news/jnj-mrk-pfe-3-pharmaceutical-stocks-addressing-global-health-challenges/>3 Pharmaceutical Stocks Addressing Global Health Challenges</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharmaceutical Stocks Addressing Global Health Challenges

3 Upcoming Dividend Increases

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs c...

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Novo Nordisk ($NVO) stock fell as its blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are lined up for Medicare price negotiatio...

Novo Nordisk's (NYSE:NVO) Ozempic and Wegovy Lined Up for Medicare Drug Price Negotiations

Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

Odyssey Therapeutics files for $100M IPO

Dividend Champion, Contender, And Challenger Highlights: Week Of January 19

ABCL

ALPMF

ALPMY

ALVO

AZNCF

CGON

CSCO

ERIE

FAST

HFBL

ILMN

IRWD

ITCI

JOUT

LAND

LKFN

ORCL

RHHBY

RHHVF

RLAY

SCHD

SCVL

SDZXF

SOMC

TBPH

TCHBF

TYCB

Screenshot 2024-11-20 at 6.30.30 PM

BRTX

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

Pfizer Declares First-Quarter 2025 Dividend

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

Roam For the Holidays: Grindr Offers Free Access to Their Popular Travel Feature

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Stuart Therapeutics Announces the Appointment of Two New Board Members

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Comments

Pfizer

ニュース

最新ニュース Pfizer (NYSE:PFE) 株価情報

火曜日, 5 07, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル